Phaarmasia

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE486I01016
  • NSEID:
  • BSEID: 523620
INR
117.15
-2.3 (-1.93%)
BSENSE

Jan 19

BSE+NSE Vol: 2.68 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Phaarmasia
Mercury Labs
Concord Drugs
Ajooni Biotech
Source Natural
Mangalam Drugs
Bharat Immunolog
Amwill Health
Asston Pharmaceu
Accretion Pha.
Zenith Drugs

Why is Phaarmasia Ltd ?

1
Weak Long Term Fundamental Strength with a -12.60% CAGR growth in Operating Profits over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.26
  • The company has reported losses. Due to this company has reported negative ROCE
2
With a growth in Net Profit of 544.44%, the company declared Very Positive results in Sep 25
  • NET SALES(Latest six months) At Rs 23.42 cr has Grown at 64.70%
  • PAT(Q) At Rs 1.74 cr has Grown at 535.0% (vs previous 4Q average)
  • ROCE(HY) Highest at 7.91%
3
With ROE of 7.3, it has a Very Expensive valuation with a 7.6 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 149.26%, its profits have risen by 123% ; the PEG ratio of the company is 0.4
4
Majority shareholders : Promoters
5
Consistent Returns over the last 3 years
  • Along with generating 149.26% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Phaarmasia should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Phaarmasia for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Phaarmasia
149.26%
2.67
55.91%
Sensex
8.65%
0.76
11.31%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
8.85%
EBIT Growth (5y)
-12.60%
EBIT to Interest (avg)
-1.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
2.35
Tax Ratio
2.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
-10.15%
ROE (avg)
1.45%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
105
Industry P/E
33
Price to Book Value
7.59
EV to EBIT
81.12
EV to EBITDA
81.12
EV to Capital Employed
7.87
EV to Sales
2.42
PEG Ratio
0.38
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
7.26%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company
NET SALES(Latest six months)

At Rs 23.42 cr has Grown at 64.70%

PAT(Q)

At Rs 1.74 cr has Grown at 535.0% (vs previous 4Q average

ROCE(HY)

Highest at 7.91%

PBDIT(Q)

Highest at Rs 1.61 cr.

PBT LESS OI(Q)

Highest at Rs 1.56 cr.

EPS(Q)

Highest at Rs 2.55

-2What is not working for the Company
DEBTORS TURNOVER RATIO(HY)

Lowest at 2.44 times

Loading Valuation Snapshot...

Here's what is working for Phaarmasia

Profit After Tax (PAT) - Quarterly
At Rs 1.74 cr has Grown at 535.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs -0.40 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Latest six months
At Rs 23.42 cr has Grown at 64.70%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.61 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.56 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 1.74 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 2.55
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Phaarmasia

Debtors Turnover Ratio- Half Yearly
Lowest at 2.44 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio